Feature Article

Clonal Cytopenias of Undetermined Significance: Potential Predictor of Myeloid Malignancies?

Abstract: The recent identification of the potential for clonal replication in patients with unexplained cytopenias, resulting in myelodysplastic syndrome (MDS) or myeloid malignancies, has opened the […]

Evolving Third-Line Treatment Options for Follicular Lymphoma

H&O What led to the recent withdrawals of phosphoinositide 3-kinase (PI3K) inhibitors in the setting of follicular lymphoma? JB  In the past few months, several PI3K […]

Feature Article

Follicular Lymphoma Grade 3: A Comprehensive Review 

Abstract: Follicular lymphoma (FL) is a heterogeneous entity with disparate outcomes based on clinical and pathologic characteristics. An increasingly detailed understanding of high-grade FL (grade 3) […]

Letter From the Editor

Letter From the Editor: Debate, Argument, or Discussion?

At a recent debate on the treatment of CLL, I was going head-to-head with a colleague regarding whether BTK inhibitors or venetoclax should be first-line therapy. […]

Drug Development

Is the Use of Progression-Free Survival a Valid Endpoint for Trials of Drug Combinations in Oncology?

H&O  What are the goals of treatment in cancer, and have they changed over the years? IT  The ultimate goals of treatment of any disease are […]

HCC In Focus

Exploring the Potential Chemoprophylactic Role of Carvedilol for Hepatocellular Carcinoma

H&O  What are the notable risk factors for hepatocellular carcinoma? RS  The main risk factor for hepatocellular carcinoma (HCC) is liver cirrhosis. A damaged liver with […]

CLL

The Use of Chimeric Antigen T-Cell Therapy in Chronic Lymphocytic Leukemia

H&O  What options are available for patients with chronic lymphocytic leukemia (CLL) that is refractory to Bruton tyrosine kinase (BTK) inhibitors and venetoclax?  TS  This is […]

Breast Cancer In Focus

New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

H&O  What is standard endocrine therapy in estrogen receptor (ER)–positive breast cancer? EH  The selective estrogen receptor modulator (SERM) tamoxifen, which was first introduced in the […]

Melanoma in Focus

The Role of Triple Therapy in BRAF-Positive Melanoma

H&O  How common is BRAF-positive melanoma? RS  Melanoma is BRAF-positive in approximately 50% of cases that arise on the skin; 10% to 20% of cases that […]